NO20020130L - Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis - Google Patents
Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksisInfo
- Publication number
- NO20020130L NO20020130L NO20020130A NO20020130A NO20020130L NO 20020130 L NO20020130 L NO 20020130L NO 20020130 A NO20020130 A NO 20020130A NO 20020130 A NO20020130 A NO 20020130A NO 20020130 L NO20020130 L NO 20020130L
- Authority
- NO
- Norway
- Prior art keywords
- cell migration
- fviia
- chemotaxis
- gene expression
- tissue factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901023 | 1999-07-14 | ||
| US14830099P | 1999-08-11 | 1999-08-11 | |
| DKPA199901117 | 1999-08-12 | ||
| PCT/DK2000/000401 WO2001005353A2 (en) | 1999-07-14 | 2000-07-14 | USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20020130D0 NO20020130D0 (no) | 2002-01-11 |
| NO20020130L true NO20020130L (no) | 2002-03-13 |
Family
ID=27221063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020130A NO20020130L (no) | 1999-07-14 | 2002-01-11 | Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20020193302A1 (de) |
| EP (1) | EP1200116B1 (de) |
| JP (1) | JP2003525028A (de) |
| KR (1) | KR100821644B1 (de) |
| CN (1) | CN100411684C (de) |
| AT (1) | ATE411041T1 (de) |
| AU (1) | AU5807500A (de) |
| BR (1) | BR0012408A (de) |
| CA (1) | CA2378249A1 (de) |
| CZ (1) | CZ200240A3 (de) |
| DE (1) | DE60040539D1 (de) |
| ES (1) | ES2316372T3 (de) |
| HU (1) | HUP0302052A3 (de) |
| IL (1) | IL147294A0 (de) |
| MX (1) | MXPA02000468A (de) |
| NO (1) | NO20020130L (de) |
| PL (1) | PL353035A1 (de) |
| RU (1) | RU2268744C2 (de) |
| WO (1) | WO2001005353A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271365A1 (en) * | 2000-06-21 | 2002-01-02 | Wyeth | Cyr61 as a target for treatment and diagnosis of breast cancer |
| DE10238429A1 (de) | 2002-03-19 | 2003-10-30 | Aventis Behring Gmbh Intellect | Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose |
| US6858587B2 (en) | 2001-11-02 | 2005-02-22 | Novo Nordisk Pharmaceuticals, Inc. | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| EP1443956A2 (de) * | 2001-11-02 | 2004-08-11 | Novo Nordisk Health Care AG | Verwendung des gewebefaktor-agonisten oder gewebefaktor-antagonisten zur behandlung von erkrankungen im zusammenhang mit apoptose |
| EP1471818A4 (de) * | 2002-02-04 | 2007-03-28 | Millennium Pharm Inc | Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen unter verwendung von 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 oder 13249 molekülen |
| CA2534996A1 (en) * | 2003-08-06 | 2005-05-06 | Hans Prydz | The use of sirna silencing in the prevention of metastasis |
| KR20070012715A (ko) * | 2004-04-16 | 2007-01-26 | 더 스크립스 리서치 인스티튜트 | 혈관신생 조절방법 |
| US20100028358A1 (en) * | 2005-11-07 | 2010-02-04 | Wolfram Ruf | Compositions and Methods for Controlling Tissue Factor Signaling Specificity |
| WO2008103812A1 (en) * | 2007-02-21 | 2008-08-28 | Yale University | Compositions and methods for diagnosing and treating endometriosis |
| JP5905258B2 (ja) | 2011-07-01 | 2016-04-20 | 株式会社 資生堂 | 血小板由来成長因子−bb産生亢進剤、並びにそれを含む間葉系幹細胞産生促進剤、幹細胞安定化剤、及び真皮再生化剤 |
| CN109381478A (zh) * | 2018-10-31 | 2019-02-26 | 青岛大学附属医院 | 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123338C1 (ru) * | 1990-06-15 | 1998-12-20 | Сайтел Корпорейшн | Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения |
| AU2793292A (en) * | 1991-10-11 | 1993-05-03 | Novo Nordisk A/S | Hemostatic composition for local hemostasis |
| DE19538715A1 (de) * | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| JP4307552B2 (ja) * | 1996-03-15 | 2009-08-05 | ミューニン コーポレイション | 細胞外マトリックスシグナリング分子 |
| WO1998058661A1 (en) | 1997-06-23 | 1998-12-30 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
| US20030040481A1 (en) * | 1997-07-18 | 2003-02-27 | Lars Kongsbak | Methods for modifying cell motility using a factor VIIa antagonist |
| ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
| AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| ES2432967T3 (es) | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
| IL158615A0 (en) | 2001-05-02 | 2004-05-12 | Novo Nordisk As | Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome |
| IL159622A0 (en) | 2001-07-20 | 2004-06-01 | Novo Nordisk Healthcare Ag | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| EP1446155A1 (de) | 2001-11-09 | 2004-08-18 | Novo Nordisk A/S | Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und aprotinin-polypeptiden |
| JP2006510568A (ja) | 2001-11-09 | 2006-03-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物 |
| EP1446147A1 (de) | 2001-11-09 | 2004-08-18 | Novo Nordisk Health Care AG | Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält |
| JP2005511599A (ja) | 2001-11-09 | 2005-04-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチド及びv因子ポリペプチドを含む薬学的組成物 |
-
2000
- 2000-07-14 KR KR1020027000527A patent/KR100821644B1/ko not_active Expired - Fee Related
- 2000-07-14 AU AU58075/00A patent/AU5807500A/en not_active Abandoned
- 2000-07-14 EP EP00943706A patent/EP1200116B1/de not_active Expired - Lifetime
- 2000-07-14 IL IL14729400A patent/IL147294A0/xx unknown
- 2000-07-14 DE DE60040539T patent/DE60040539D1/de not_active Expired - Lifetime
- 2000-07-14 RU RU2002103602/15A patent/RU2268744C2/ru not_active IP Right Cessation
- 2000-07-14 CZ CZ200240A patent/CZ200240A3/cs unknown
- 2000-07-14 AT AT00943706T patent/ATE411041T1/de not_active IP Right Cessation
- 2000-07-14 PL PL00353035A patent/PL353035A1/xx not_active Application Discontinuation
- 2000-07-14 BR BR0012408-7A patent/BR0012408A/pt not_active Application Discontinuation
- 2000-07-14 JP JP2001510411A patent/JP2003525028A/ja active Pending
- 2000-07-14 CN CNB008102287A patent/CN100411684C/zh not_active Expired - Fee Related
- 2000-07-14 MX MXPA02000468A patent/MXPA02000468A/es not_active Application Discontinuation
- 2000-07-14 WO PCT/DK2000/000401 patent/WO2001005353A2/en not_active Ceased
- 2000-07-14 CA CA002378249A patent/CA2378249A1/en not_active Abandoned
- 2000-07-14 HU HU0302052A patent/HUP0302052A3/hu unknown
- 2000-07-14 ES ES00943706T patent/ES2316372T3/es not_active Expired - Lifetime
-
2002
- 2002-01-11 NO NO20020130A patent/NO20020130L/no unknown
- 2002-01-14 US US10/051,044 patent/US20020193302A1/en not_active Abandoned
-
2005
- 2005-06-14 US US11/152,468 patent/US20050239708A1/en not_active Abandoned
-
2008
- 2008-07-23 US US12/178,126 patent/US7829529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100411684C (zh) | 2008-08-20 |
| EP1200116B1 (de) | 2008-10-15 |
| JP2003525028A (ja) | 2003-08-26 |
| WO2001005353A2 (en) | 2001-01-25 |
| KR100821644B1 (ko) | 2008-04-11 |
| PL353035A1 (en) | 2003-10-06 |
| AU5807500A (en) | 2001-02-05 |
| ES2316372T3 (es) | 2009-04-16 |
| NO20020130D0 (no) | 2002-01-11 |
| MXPA02000468A (es) | 2008-10-06 |
| EP1200116A2 (de) | 2002-05-02 |
| BR0012408A (pt) | 2002-03-12 |
| US20020193302A1 (en) | 2002-12-19 |
| DE60040539D1 (de) | 2008-11-27 |
| RU2268744C2 (ru) | 2006-01-27 |
| WO2001005353A3 (en) | 2001-07-19 |
| HUP0302052A3 (en) | 2005-12-28 |
| CA2378249A1 (en) | 2001-01-25 |
| US7829529B2 (en) | 2010-11-09 |
| US20050239708A1 (en) | 2005-10-27 |
| US20090036378A1 (en) | 2009-02-05 |
| ATE411041T1 (de) | 2008-10-15 |
| CZ200240A3 (cs) | 2003-04-16 |
| KR20020025194A (ko) | 2002-04-03 |
| HUP0302052A2 (hu) | 2003-09-29 |
| CN1460024A (zh) | 2003-12-03 |
| IL147294A0 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50310980D1 (de) | VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE | |
| NO20020130D0 (no) | Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrering eller kjemotaksis | |
| NO961888D0 (no) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser | |
| EP1581056A4 (de) | Therapeutische retrovirus-vektoren für diegentherapie | |
| BR9811956B1 (pt) | naftiridinonas e composição farmacêutica compreendendo as mesmas. | |
| ATE368731T1 (de) | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen | |
| AU5338301A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE324105T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken | |
| MX2009004051A (es) | Uso de antagonistas de il-1 para tratar gota y pseudo gota. | |
| DK1218494T3 (da) | Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler | |
| ATE275919T1 (de) | Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen | |
| DE69738887D1 (de) | Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen | |
| DK1171144T3 (da) | Anvendelse af tetrahydrocurcuminoider til regulering af fysiologiske og patologiske forhold i huden og slimhinderne | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| ATE427773T1 (de) | Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-a1,3,4- xadiazol-2-yluphenyl)pyridin-3- sulphonamid in der tumortherapie | |
| ATE362923T1 (de) | 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen | |
| BR0315344A (pt) | Métodos para prever edema como um efeito colateral do tratamento com drogas | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| ATE242641T1 (de) | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation | |
| ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| NO20010390L (no) | Behandling av angstsykdommer | |
| ATE376416T1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen | |
| NO20045343L (no) | Ny kombinasjon for behandling av luftveisforstyrrelser |